Amycretin vs Semaglutide
How they differ
- FDA status. Amycretin: In clinical trials; not FDA-approved.1,2 Semaglutide: FDA-approved as Ozempic, Rybelsus and Wegovy.3,4,5,6
- Kinds of studies cited. Amycretin: smaller controlled human trials. Semaglutide: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Amycretin | Semaglutide |
|---|---|---|
| What it is | An investigational single-molecule agonist of the GLP-1 and amylin receptors from Novo Nordisk. The 2026 Phase 2 report names it zenagamtide (formerly amycretin) and says it also acts on calcitonin receptors.1,2 | A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.3 |
| FDA status | In clinical trials In clinical trials; not FDA-approved1,2 Not FDA-approved. The sources reviewed here describe it only in clinical trials sponsored by Novo Nordisk, including registered Phase 3 trials.1,2,7,8,9,10,11,12 | FDA-approved FDA-approved as Ozempic, Rybelsus and Wegovy3,4,5,6 FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.3,4,5,6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.13 | Not among the six peptides the policy lists.13 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited | Smaller controlled human trials
|
|
| Records collected | 140 ClinicalTrials.gov records and 108 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗
The Lancet · Official source · Source checked November 14, 2026
- 3WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 4Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 7ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 8ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 9ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 10ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 11ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 12ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 13HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 14Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (2025) · PMID 40550229 ↗
The Lancet · Official source · Source checked November 14, 2026
- 15Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (2025) · PMID 40550231 ↗
The Lancet · Official source · Source checked November 14, 2026
- 16FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 17FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026